Letters to the Editor
January 2001

Genetic Determinants of Clozapine-Induced Agranulocytosis: Recent Results of HLA Subtyping in a Non-Jewish Caucasian Sample

Author Affiliations

Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001

Arch Gen Psychiatry. 2001;58(1):93-94. doi:10.1001/archpsyc.58.1.93

The incidence of agranulocytosis in clozapine-treated patients is comparatively high despite the undisputed clinical advantages of clozapine.1 The mechanisms of clozapine-induced agranulocytosis (CA) are debatable2; however, there are some findings indicative of an idiosyncratic drug reaction, pointing to a genetic basis of this adverse effect.3 Some studies suggest that specific HLA haplotypes are associated with a patient's susceptibility to developing CA.48 In these studies, HLA subtyping of Jewish and non-Jewish Caucasian patients with and without CA was performed. Clozapine-induced agranulocytosis was associated with HLA-B38, DRB1*0402, DRB4*0101, DQB1*0201, and DQB1*0302 haplotypes in Jewish and HLA-DR*02, DRB1*1601, DRB5*02, and DQB1*0502 in non-Jewish Caucasian patients47; the presence of HLA-B35 seemed to be a protective factor against CA in the latter group.8 However, each of these studies had statistical and/or methological shortcomings, such as small sample size, lack of clinical descriptions of study subjects, or insufficient information about the study design.

First Page Preview View Large
First page PDF preview
First page PDF preview